Neuraxis, Inc. Form 8-K Summary
Reporting date: November 9, 2023; the report was signed and filed November 14, 2023. The filing reports a material financing agreement rather than periodic financial results. Neuraxis is an emerging growth company whose common stock trades on the NYSE American under “NRXS.”
Material Financing and Key Terms
- Neuraxis entered into a securities purchase agreement with Flagstaff International, LLC for the issuance of Series B Convertible Preferred Stock.
- The stated purchase price is $2.38 per preferred share, with an aggregate commitment of $3.0 million.
- Payment is scheduled in 15 monthly installments of $200,000 each, beginning on the later of January 10, 2024, or a date after stockholder approval of an amendment authorizing the Series B Preferred Stock.
- The Series B Preferred Stock will be convertible at any time into common stock without additional consideration. The filing text does not provide a clear conversion ratio or maximum number of common shares issuable.
- Closing is subject to stockholder approval and the filing of a Certificate of Designation with the Delaware Secretary of State.
- Upon issuance, the Series B Preferred Stock will rank senior to common stock with respect to liquidation, dissolution, and winding-up payments.
Registration Rights
Under a related Registration Rights Agreement, holders of a majority of the outstanding registrable securities may request registration of all or part of those securities. Neuraxis must notify other holders, file a resale registration statement with the SEC within 60 days after the initial request, and use its best efforts to obtain effectiveness.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt balances, cash balances, liquidity measures, or other periodic financial metrics. The proposed transaction would provide up to $3.0 million of financing, subject to stockholder approval and the scheduled installment payments; the filing does not state whether any proceeds had been received as of the filing date.
Outlook, Risks, and Unusual Items
- Completion of the financing depends on stockholder approval and the related corporate charter amendment.
- The financing is structured as monthly installments rather than an immediately funded lump sum, creating timing and funding uncertainty.
- Conversion of the preferred stock could dilute existing common stockholders; the filing does not state the conversion ratio or potential dilution.
- The preferred stock’s senior liquidation preference may reduce the recovery available to common stockholders in a liquidation or winding-up.
- Registration rights could facilitate resale of the underlying securities and may affect the trading market for the common stock.
- The filing contains no formal financial guidance or detailed management outlook.
Investor Verification Checklist
- Confirm stockholder approval of the charter amendment and the filing of the Series B Certificate of Designation.
- Review the full Securities Purchase Agreement and Registration Rights Agreement filed as Exhibits 10.1 and 10.2.
- Verify the actual amount and timing of each installment received.
- Determine the preferred-to-common conversion ratio, potential share issuance, and resulting dilution.
- Review subsequent SEC filings for registration statements, conversions, amendments, defaults, or changes to the financing terms.